A M Woodward1, T A Davis, A G S Silva, J A Kirk, J A Leary. 1. Familial Cancer Service, Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.
Abstract
INTRODUCTION: A strong family history of breast and/or ovarian cancer can often be explained by small insertions, deletions, or substitutions in BRCA1 or BRCA2 and large genomic rearrangements in BRCA1. However, there is little evidence that genomic rearrangements are a major factor in BRCA2 associated breast cancer and the frequencies of rearrangements in BRCA1 in large clinic based populations are unknown. OBJECTIVE: To investigate the frequency of large genomic rearrangements in BRCA1 and BRCA2 in a large clinic based population at high risk of developing breast and/or ovarian cancer. METHODS: Multiplex ligation dependent probe amplification was used to comprehensively screen BRCA1 and/or BRCA2 in 312 index cases. RESULTS: Three novel deletions detected in BRCA2 were found exclusively in families with at least one case of male breast cancer. Novel rearrangements in BRCA1 were detected mostly in families with both breast and ovarian cancer. Families with these mutations were significantly younger at average age of cancer diagnosis. CONCLUSION: Screening for large genomic rearrangements in both BRCA1 and BRCA2 is strongly supported by this study, in particular in multiple case breast/ovarian families with a young age of onset (BRCA1) and families containing at least one case of male breast cancer (BRCA2).
INTRODUCTION: A strong family history of breast and/or ovarian cancer can often be explained by small insertions, deletions, or substitutions in BRCA1 or BRCA2 and large genomic rearrangements in BRCA1. However, there is little evidence that genomic rearrangements are a major factor in BRCA2 associated breast cancer and the frequencies of rearrangements in BRCA1 in large clinic based populations are unknown. OBJECTIVE: To investigate the frequency of large genomic rearrangements in BRCA1 and BRCA2 in a large clinic based population at high risk of developing breast and/or ovarian cancer. METHODS: Multiplex ligation dependent probe amplification was used to comprehensively screen BRCA1 and/or BRCA2 in 312 index cases. RESULTS: Three novel deletions detected in BRCA2 were found exclusively in families with at least one case of male breast cancer. Novel rearrangements in BRCA1 were detected mostly in families with both breast and ovarian cancer. Families with these mutations were significantly younger at average age of cancer diagnosis. CONCLUSION: Screening for large genomic rearrangements in both BRCA1 and BRCA2 is strongly supported by this study, in particular in multiple case breast/ovarian families with a young age of onset (BRCA1) and families containing at least one case of male breast cancer (BRCA2).
Authors: D G R Evans; Mike Bulman; Karen Young; Emma Howard; Stuart Bayliss; Andrew Wallace; Fiona Lalloo Journal: Fam Cancer Date: 2007-07-17 Impact factor: 2.375
Authors: F Casilli; I Tournier; O M Sinilnikova; F Coulet; F Soubrier; C Houdayer; A Hardouin; P Berthet; H Sobol; V Bourdon; D Muller; J P Fricker; C Capoulade-Metay; A Chompret; C Nogues; S Mazoyer; P Chappuis; P Maillet; C Philippe; A Lortholary; P Gesta; S Bézieau; C Toulas; L Gladieff; C M Maugard; D M Provencher; C Dugast; C Delvincourt; T D Nguyen; L Faivre; V Bonadona; T Frébourg; R Lidereau; D Stoppa-Lyonnet; M Tosi Journal: J Med Genet Date: 2006-09 Impact factor: 6.318
Authors: Maurizia Dalla Palma; Susan M Domchek; Jill Stopfer; Julie Erlichman; Jill D Siegfried; Jessica Tigges-Cardwell; Bernard A Mason; Timothy R Rebbeck; Katherine L Nathanson Journal: Cancer Res Date: 2008-08-14 Impact factor: 12.701
Authors: Helena Rudnicka; Tadeusz Debniak; Cezary Cybulski; Tomasz Huzarski; Jacek Gronwald; Jan Lubinski; Bohdan Gorski Journal: Mol Biol Rep Date: 2013-09-25 Impact factor: 2.316
Authors: Amanda Gonçalves Silva; Ingrid Petroni Ewald; Marina Sapienza; Manuela Pinheiro; Ana Peixoto; Amanda França de Nóbrega; Dirce M Carraro; Manuel R Teixeira; Patricia Ashton-Prolla; Maria Isabel W Achatz; Carla Rosenberg; Ana C V Krepischi Journal: BMC Cancer Date: 2012-06-12 Impact factor: 4.430